Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Качество жизни пациентов с гиперчувствительным пневмонитом в реальной клинической практике
Качество жизни пациентов с гиперчувствительным пневмонитом в реальной клинической практике
Суворова О.А., Трушенко Н.В., Лавгинова Б.Б., Левина Ю.А., Мержоева З.М., Авдеев С.Н. Качество жизни пациентов с гиперчувствительным пневмонитом в реальной клинической практике. Consilium Medicum. 2025;27(8):488–494. DOI: 10.26442/20751753.2025.8.203403
© ООО «КОНСИЛИУМ МЕДИКУМ», 2025 г.
© ООО «КОНСИЛИУМ МЕДИКУМ», 2025 г.
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Аннотация
Введение. Гиперчувствительный пневмонит (ГП) – иммуноопосредованное интерстициальное заболевание легких, часто приводящее к легочному фиброзу, что ухудшает качество жизни (КЖ) пациентов.
Цель. Оценка КЖ у пациентов с различными фенотипами ГП с использованием опросников K-BILD и EQ-5D-5L и выявление клинических и функциональных параметров, значимо влияющих на КЖ.
Материалы и методы. В исследование включены 105 пациентов с ГП [33 – нефиброзный (нфГП), 72 – фиброзный (фГП), из них 32 – с паттерном обычной интерстициальной пневмонии (ОИП) по высокоразрешающей компьютерной томографии]. Кроме КЖ, оценивали демографические и клинические данные, параметры функции дыхания и эхокардиограммы, одышку по шкале mMRC и кашель по Визуальной аналоговой шкале и опроснику LCQ, результаты теста 6-минутной ходьбы (6МТХ), изменения по высокоразрешающей компьютерной томографии исходно и через 12 мес. Статистический анализ включал непараметрические методы сравнения 2 групп, корреляционный анализ, линейную и множественную регрессию.
Результаты. Пациенты с фГП характеризовались более длительным стажем заболевания, более выраженными симптомами, сниженной функцией легких и худшими показателями КЖ по шкалам K-BILD и EQ-5D-5L. При этом пациенты с фГП+ОИП демонстрировали худшие показатели функции легких, более длительное течение заболевания и более частое прогрессирование заболевания, однако не отличались по КЖ от пациентов с фГП без ОИП. По опроснику K-BILD наибольшее влияние на КЖ оказали выраженность кашля (LCQ), дистанция в 6МТХ и форсированная жизненная емкость легких. На индекс EQ-5D-5L наиболее значимое влияние оказывала дистанции 6МТХ.
Заключение. Пациенты с фГП и паттерном ОИП характеризуются более тяжелым течением заболевания по сравнению с нфГП. Опросники K-BILD и EQ-5D-5L можно считать надежными инструментами оценки КЖ при ГП. Наибольшее влияние на КЖ оказывают выраженность кашля, форсированная жизненная емкость легких и толерантность к физической нагрузке.
Ключевые слова: интерстициальные заболевания легких, гиперчувстительный пневмонит, качество жизни, K-BILD, EQ-5D-5L, LCQ
Aim. To assess QOL in patients with different HP phenotypes using the K-BILD and EQ-5D-5L questionnaires and identify clinical and functional factors affecting QOL.
Materials and methods. The study included 105 HP patients [33 non-fibrotic (nfHP), 72 fibrotic (fHP), 32 with usual interstitial pneumonia (UIP) pattern on high-resolution computed tomography]. QOL, clinical data, respiratory function, echocardiography, dyspnea (mMRC scale), cough (VAS scale, LCQ), 6MWT results, and high-resolution computed tomography changes over 12 months were assessed. Statistical analysis involved nonparametric methods, correlation, linear, and multiple regression.
Results. fHP and nfHP patients showed significant differences. fHP patients had a longer disease duration, more severe symptoms, lower lung function, and worse QOL. Those with fHP+UIP had worse lung function and more disease progression but similar QOL to fHP patients without UIP. For K-BILD, cough severity (LCQ), 6MWT distance, and forced vital capacity most affected QOL. For EQ-5D-5L, the 6MWT distance was the key factor.
Conclusion. fHP patients experience a more severe disease course than nfHP patients. UIP pattern correlates with a more aggressive clinical progression. K-BILD and EQ-5D-5L are reliable tools for assessing QOL in HP. The greatest influence on QOL is exerted by the severity of cough, forced vital capacity and exercise tolerance.
Keywords: interstitial lung diseases, hypersensitivity pneumonitis, quality of life, KBILD, EQ-5D-5L, LCQ
Цель. Оценка КЖ у пациентов с различными фенотипами ГП с использованием опросников K-BILD и EQ-5D-5L и выявление клинических и функциональных параметров, значимо влияющих на КЖ.
Материалы и методы. В исследование включены 105 пациентов с ГП [33 – нефиброзный (нфГП), 72 – фиброзный (фГП), из них 32 – с паттерном обычной интерстициальной пневмонии (ОИП) по высокоразрешающей компьютерной томографии]. Кроме КЖ, оценивали демографические и клинические данные, параметры функции дыхания и эхокардиограммы, одышку по шкале mMRC и кашель по Визуальной аналоговой шкале и опроснику LCQ, результаты теста 6-минутной ходьбы (6МТХ), изменения по высокоразрешающей компьютерной томографии исходно и через 12 мес. Статистический анализ включал непараметрические методы сравнения 2 групп, корреляционный анализ, линейную и множественную регрессию.
Результаты. Пациенты с фГП характеризовались более длительным стажем заболевания, более выраженными симптомами, сниженной функцией легких и худшими показателями КЖ по шкалам K-BILD и EQ-5D-5L. При этом пациенты с фГП+ОИП демонстрировали худшие показатели функции легких, более длительное течение заболевания и более частое прогрессирование заболевания, однако не отличались по КЖ от пациентов с фГП без ОИП. По опроснику K-BILD наибольшее влияние на КЖ оказали выраженность кашля (LCQ), дистанция в 6МТХ и форсированная жизненная емкость легких. На индекс EQ-5D-5L наиболее значимое влияние оказывала дистанции 6МТХ.
Заключение. Пациенты с фГП и паттерном ОИП характеризуются более тяжелым течением заболевания по сравнению с нфГП. Опросники K-BILD и EQ-5D-5L можно считать надежными инструментами оценки КЖ при ГП. Наибольшее влияние на КЖ оказывают выраженность кашля, форсированная жизненная емкость легких и толерантность к физической нагрузке.
Ключевые слова: интерстициальные заболевания легких, гиперчувстительный пневмонит, качество жизни, K-BILD, EQ-5D-5L, LCQ
________________________________________________
Aim. To assess QOL in patients with different HP phenotypes using the K-BILD and EQ-5D-5L questionnaires and identify clinical and functional factors affecting QOL.
Materials and methods. The study included 105 HP patients [33 non-fibrotic (nfHP), 72 fibrotic (fHP), 32 with usual interstitial pneumonia (UIP) pattern on high-resolution computed tomography]. QOL, clinical data, respiratory function, echocardiography, dyspnea (mMRC scale), cough (VAS scale, LCQ), 6MWT results, and high-resolution computed tomography changes over 12 months were assessed. Statistical analysis involved nonparametric methods, correlation, linear, and multiple regression.
Results. fHP and nfHP patients showed significant differences. fHP patients had a longer disease duration, more severe symptoms, lower lung function, and worse QOL. Those with fHP+UIP had worse lung function and more disease progression but similar QOL to fHP patients without UIP. For K-BILD, cough severity (LCQ), 6MWT distance, and forced vital capacity most affected QOL. For EQ-5D-5L, the 6MWT distance was the key factor.
Conclusion. fHP patients experience a more severe disease course than nfHP patients. UIP pattern correlates with a more aggressive clinical progression. K-BILD and EQ-5D-5L are reliable tools for assessing QOL in HP. The greatest influence on QOL is exerted by the severity of cough, forced vital capacity and exercise tolerance.
Keywords: interstitial lung diseases, hypersensitivity pneumonitis, quality of life, KBILD, EQ-5D-5L, LCQ
Полный текст
Список литературы
1. Raghu G, Remy-Jardin M, Ryerson CJ, et al. Diagnosis of Hypersensitivity Pneumonitis in Adults. An Official ATS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med. 2020;202(3):e36-69. DOI:10.1164/rccm.202005-2032ST
2. Авдеев С.Н., Айсанов З.Р., Визель А.А., и др. Гиперчувствительный пневмонит: федеральные клинические рекомендации по диагностике и лечению. Пульмонология. 2025;35(1):16–41 [Avdeev SN, Aisanov ZR, Vizel AA, et al. Federal clinical guidelines on diagnosis and treatment of hypersensitivity pneumonitis. Pulmonologiya. 2025;35(1):16-41 (in Russian)]. DOI:10.18093/0869-0189-2025-35-1-16-41
3. Raghu G, Remy-Jardin M, Richeldi L, et al. Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med. 2022;205(9):e18-47. DOI:10.1164/rccm.202202-0399ST
4. Adams TN, Batra K, Kypreos M, Glazer CS. Impact of radiographic honeycombing on transplant free survival and efficacy of immunosuppression in fibrotic hypersensitivity pneumonitis. BMC Pulm Med. 2023;23(1):224. DOI:10.1186/s12890-023-02523-3
5. Aronson KI, Rajan M, Varadarajan J, et al. Development and initial validation of a disease-specific instrument to measure health-related quality of life in hypersensitivity pneumonitis. ERJ Open Res. 2024;10(4):00155-2024. DOI:10.1183/23120541.00155-2024
6. Lubin M, Chen H, Elicker B, et al. A comparison of health-related quality of life in idiopathic pulmonary fibrosis and chronic hypersensitivity pneumonitis. Chest. 2014;145(6):1333-8. DOI:10.1378/chest.13-1984
7. Patel AS, Siegert RJ, Brignall K, et al. The development and validation of the King's Brief Interstitial Lung Disease (K-BILD) health status questionnaire. Thorax. 2012;67(9):804-10. DOI:10.1136/thoraxjnl-2012-201581
8. Cox IA, Campbell J, de Graaff B, et al. Assessment of health-related quality of life in Australian patients with idiopathic pulmonary fibrosis: a comparison of the EQ-5D-5L and the AHRQL-8D. Qual Life Res. 2023;32(2):473-93. DOI:10.1007/s11136-022-03205-z
9. Takei R, Matsuda T, Fukihara J, et al. Changes in patient-reported outcomes in patients with non-idiopathic pulmonary fibrosis fibrotic interstitial lung disease and progressive pulmonary fibrosis. Front Med (Lausanne). 2023;10:1067149. DOI:10.3389/fmed.2023.1067149
10. Birring SS, Prudon B, Carr AJ, et al. Development of a symptom specific health status measure for patients with chronic cough: Leicester Cough Questionnaire (LCQ). Thorax. 2003;58(4):339-43. DOI:10.1136/thorax.58.4.339
11. Stanojevic S, Kaminsky DA, Miller MR, et al. ERS/ATS technical standard on interpretive strategies for routine lung function tests. Eur Respir J. 2022;60(1):2101499. DOI:10.1183/13993003.01499-2021
12. Rautajoki T, Rantala HA, Sutinen E, et al. Health-related quality of life measured with K-BILD is associated with survival in patients with idiopathic pulmonary fibrosis. BMC Pulm Med. 2024;24(1):480. DOI:10.1186/s12890-024-03303-3
13. Omelyanovskiy V, Musina N, Ratushnyak S, et al. Valuation of the EQ-5D-3L in Russia. Qual Life Res. 2021;30(7):1997-2007. DOI:10.1007/s11136-021-02804-6
14. Hasan S, Verma A, Haque S, et al. A clinical study to monitor prescription patterns, clinical outcomes, and adverse drug reactions among patients of various interstitial lung diseases attending respiratory medicine outpatient department at tertiary care hospital in Northern India. Perspect Clin Res. 2024;15(3):141-6. DOI:10.4103/picr.picr_108_23
15. Lobo LJ, Liu Y, Li P, et al. Design and baseline characteristics of the ILD-PRO registry in patients with progressive pulmonary fibrosis. BMC Pulm Med. 2024;24(1):468. DOI:10.1186/s12890-024-03247-8
16. Julia-Serda G, Navarro-Esteva J, Doreste-Salgado L, et al. Survival and lung function changes in hypersensitivity pneumonitis according to radiological phenotypes compared with idiopathic pulmonary fibrosis. Cureus. 2024;16(3):e57307. DOI:10.7759/cureus.57307
17. Prior TS, Hilberg O, Shaker SB, et al. Validation of the King's Brief Interstitial Lung Disease questionnaire in idiopathic pulmonary fibrosis. BMC Pulm Med. 2019;19(1):255. DOI:10.1186/s12890-019-1018-0
18. D’Souza K, Ravichandran T, Venkatnarayan K, et al. Assessment of health-related quality of life in individuals with interstitial lung diseases in a tertiary care hospital in south India. Indian J Med Res. 2024;160(2):246-53. DOI:10.25259/IJMR_218_2024
19. Trushenko NV, Suvorova OA, Schmidt AE, et al. Updates on the Prevalence, Quality of Life, and Management of Chronic Cough in Interstitial Lung Diseases. Diagnostics. 2025;15(9):1139. DOI:10.3390/diagnostics15091139
20. Lee J, White E, Freiheit E, et al. Cough-specific quality of life predicts disease progression among patients with interstitial lung disease: data from the Pulmonary Fibrosis Foundation Patient Registry. Chest. 2022;162(3):603-13. DOI:10.1016/j.chest.2022.03.025
21. Khor YH, Johannson KA, Marcoux V, et al. Epidemiology and prognostic significance of cough in fibrotic interstitial lung disease. Am J Respir Crit Care Med. 2024;210(8):1035-44.
DOI:10.1164/rccm.202311-2101OC
22. Glaspole IN, Chapman SA, Cooper WA, et al. Health-related quality of life in idiopathic pulmonary fibrosis: data from the Australian IPF Registry. Respirology. 2017;22(5):950-6. DOI:10.1111/resp.12989
23. Maqhuzu PN, Szentes BL, Kreuter M, et al. Determinants of health-related quality of life decline in interstitial lung disease. Health Qual Life Outcomes. 2020;18:334. DOI:10.1186/s12955-020-01570-2
24. Szentes BL, Kreuter M, Bahmer T, et al. Quality of life assessment in interstitial lung diseases: a comparison of the disease-specific K-BILD with the generic EQ-5D-5L. Respir Res. 2018;19(1):101. DOI:10.1186/s12931-018-0808-x
2. Avdeev SN, Aisanov ZR, Vizel AA, et al. Federal clinical guidelines on diagnosis and treatment of hypersensitivity pneumonitis. Pulmonologiya. 2025;35(1):16-41 (in Russian). DOI:10.18093/0869-0189-2025-35-1-16-41
3. Raghu G, Remy-Jardin M, Richeldi L, et al. Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med. 2022;205(9):e18-47. DOI:10.1164/rccm.202202-0399ST
4. Adams TN, Batra K, Kypreos M, Glazer CS. Impact of radiographic honeycombing on transplant free survival and efficacy of immunosuppression in fibrotic hypersensitivity pneumonitis. BMC Pulm Med. 2023;23(1):224. DOI:10.1186/s12890-023-02523-3
5. Aronson KI, Rajan M, Varadarajan J, et al. Development and initial validation of a disease-specific instrument to measure health-related quality of life in hypersensitivity pneumonitis. ERJ Open Res. 2024;10(4):00155-2024. DOI:10.1183/23120541.00155-2024
6. Lubin M, Chen H, Elicker B, et al. A comparison of health-related quality of life in idiopathic pulmonary fibrosis and chronic hypersensitivity pneumonitis. Chest. 2014;145(6):1333-8. DOI:10.1378/chest.13-1984
7. Patel AS, Siegert RJ, Brignall K, et al. The development and validation of the King's Brief Interstitial Lung Disease (K-BILD) health status questionnaire. Thorax. 2012;67(9):804-10. DOI:10.1136/thoraxjnl-2012-201581
8. Cox IA, Campbell J, de Graaff B, et al. Assessment of health-related quality of life in Australian patients with idiopathic pulmonary fibrosis: a comparison of the EQ-5D-5L and the AHRQL-8D. Qual Life Res. 2023;32(2):473-93. DOI:10.1007/s11136-022-03205-z
9. Takei R, Matsuda T, Fukihara J, et al. Changes in patient-reported outcomes in patients with non-idiopathic pulmonary fibrosis fibrotic interstitial lung disease and progressive pulmonary fibrosis. Front Med (Lausanne). 2023;10:1067149. DOI:10.3389/fmed.2023.1067149
10. Birring SS, Prudon B, Carr AJ, et al. Development of a symptom specific health status measure for patients with chronic cough: Leicester Cough Questionnaire (LCQ). Thorax. 2003;58(4):339-43. DOI:10.1136/thorax.58.4.339
11. Stanojevic S, Kaminsky DA, Miller MR, et al. ERS/ATS technical standard on interpretive strategies for routine lung function tests. Eur Respir J. 2022;60(1):2101499. DOI:10.1183/13993003.01499-2021
12. Rautajoki T, Rantala HA, Sutinen E, et al. Health-related quality of life measured with K-BILD is associated with survival in patients with idiopathic pulmonary fibrosis. BMC Pulm Med. 2024;24(1):480. DOI:10.1186/s12890-024-03303-3
13. Omelyanovskiy V, Musina N, Ratushnyak S, et al. Valuation of the EQ-5D-3L in Russia. Qual Life Res. 2021;30(7):1997-2007. DOI:10.1007/s11136-021-02804-6
14. Hasan S, Verma A, Haque S, et al. A clinical study to monitor prescription patterns, clinical outcomes, and adverse drug reactions among patients of various interstitial lung diseases attending respiratory medicine outpatient department at tertiary care hospital in Northern India. Perspect Clin Res. 2024;15(3):141-6. DOI:10.4103/picr.picr_108_23
15. Lobo LJ, Liu Y, Li P, et al. Design and baseline characteristics of the ILD-PRO registry in patients with progressive pulmonary fibrosis. BMC Pulm Med. 2024;24(1):468. DOI:10.1186/s12890-024-03247-8
16. Julia-Serda G, Navarro-Esteva J, Doreste-Salgado L, et al. Survival and lung function changes in hypersensitivity pneumonitis according to radiological phenotypes compared with idiopathic pulmonary fibrosis. Cureus. 2024;16(3):e57307. DOI:10.7759/cureus.57307
17. Prior TS, Hilberg O, Shaker SB, et al. Validation of the King's Brief Interstitial Lung Disease questionnaire in idiopathic pulmonary fibrosis. BMC Pulm Med. 2019;19(1):255. DOI:10.1186/s12890-019-1018-0
18. D’Souza K, Ravichandran T, Venkatnarayan K, et al. Assessment of health-related quality of life in individuals with interstitial lung diseases in a tertiary care hospital in south India. Indian J Med Res. 2024;160(2):246-53. DOI:10.25259/IJMR_218_2024
19. Trushenko NV, Suvorova OA, Schmidt AE, et al. Updates on the Prevalence, Quality of Life, and Management of Chronic Cough in Interstitial Lung Diseases. Diagnostics. 2025;15(9):1139. DOI:10.3390/diagnostics15091139
20. Lee J, White E, Freiheit E, et al. Cough-specific quality of life predicts disease progression among patients with interstitial lung disease: data from the Pulmonary Fibrosis Foundation Patient Registry. Chest. 2022;162(3):603-13. DOI:10.1016/j.chest.2022.03.025
21. Khor YH, Johannson KA, Marcoux V, et al. Epidemiology and prognostic significance of cough in fibrotic interstitial lung disease. Am J Respir Crit Care Med. 2024;210(8):1035-44.
DOI:10.1164/rccm.202311-2101OC
22. Glaspole IN, Chapman SA, Cooper WA, et al. Health-related quality of life in idiopathic pulmonary fibrosis: data from the Australian IPF Registry. Respirology. 2017;22(5):950-6. DOI:10.1111/resp.12989
23. Maqhuzu PN, Szentes BL, Kreuter M, et al. Determinants of health-related quality of life decline in interstitial lung disease. Health Qual Life Outcomes. 2020;18:334. DOI:10.1186/s12955-020-01570-2
24. Szentes BL, Kreuter M, Bahmer T, et al. Quality of life assessment in interstitial lung diseases: a comparison of the disease-specific K-BILD with the generic EQ-5D-5L. Respir Res. 2018;19(1):101. DOI:10.1186/s12931-018-0808-x
2. Авдеев С.Н., Айсанов З.Р., Визель А.А., и др. Гиперчувствительный пневмонит: федеральные клинические рекомендации по диагностике и лечению. Пульмонология. 2025;35(1):16–41 [Avdeev SN, Aisanov ZR, Vizel AA, et al. Federal clinical guidelines on diagnosis and treatment of hypersensitivity pneumonitis. Pulmonologiya. 2025;35(1):16-41 (in Russian)]. DOI:10.18093/0869-0189-2025-35-1-16-41
3. Raghu G, Remy-Jardin M, Richeldi L, et al. Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med. 2022;205(9):e18-47. DOI:10.1164/rccm.202202-0399ST
4. Adams TN, Batra K, Kypreos M, Glazer CS. Impact of radiographic honeycombing on transplant free survival and efficacy of immunosuppression in fibrotic hypersensitivity pneumonitis. BMC Pulm Med. 2023;23(1):224. DOI:10.1186/s12890-023-02523-3
5. Aronson KI, Rajan M, Varadarajan J, et al. Development and initial validation of a disease-specific instrument to measure health-related quality of life in hypersensitivity pneumonitis. ERJ Open Res. 2024;10(4):00155-2024. DOI:10.1183/23120541.00155-2024
6. Lubin M, Chen H, Elicker B, et al. A comparison of health-related quality of life in idiopathic pulmonary fibrosis and chronic hypersensitivity pneumonitis. Chest. 2014;145(6):1333-8. DOI:10.1378/chest.13-1984
7. Patel AS, Siegert RJ, Brignall K, et al. The development and validation of the King's Brief Interstitial Lung Disease (K-BILD) health status questionnaire. Thorax. 2012;67(9):804-10. DOI:10.1136/thoraxjnl-2012-201581
8. Cox IA, Campbell J, de Graaff B, et al. Assessment of health-related quality of life in Australian patients with idiopathic pulmonary fibrosis: a comparison of the EQ-5D-5L and the AHRQL-8D. Qual Life Res. 2023;32(2):473-93. DOI:10.1007/s11136-022-03205-z
9. Takei R, Matsuda T, Fukihara J, et al. Changes in patient-reported outcomes in patients with non-idiopathic pulmonary fibrosis fibrotic interstitial lung disease and progressive pulmonary fibrosis. Front Med (Lausanne). 2023;10:1067149. DOI:10.3389/fmed.2023.1067149
10. Birring SS, Prudon B, Carr AJ, et al. Development of a symptom specific health status measure for patients with chronic cough: Leicester Cough Questionnaire (LCQ). Thorax. 2003;58(4):339-43. DOI:10.1136/thorax.58.4.339
11. Stanojevic S, Kaminsky DA, Miller MR, et al. ERS/ATS technical standard on interpretive strategies for routine lung function tests. Eur Respir J. 2022;60(1):2101499. DOI:10.1183/13993003.01499-2021
12. Rautajoki T, Rantala HA, Sutinen E, et al. Health-related quality of life measured with K-BILD is associated with survival in patients with idiopathic pulmonary fibrosis. BMC Pulm Med. 2024;24(1):480. DOI:10.1186/s12890-024-03303-3
13. Omelyanovskiy V, Musina N, Ratushnyak S, et al. Valuation of the EQ-5D-3L in Russia. Qual Life Res. 2021;30(7):1997-2007. DOI:10.1007/s11136-021-02804-6
14. Hasan S, Verma A, Haque S, et al. A clinical study to monitor prescription patterns, clinical outcomes, and adverse drug reactions among patients of various interstitial lung diseases attending respiratory medicine outpatient department at tertiary care hospital in Northern India. Perspect Clin Res. 2024;15(3):141-6. DOI:10.4103/picr.picr_108_23
15. Lobo LJ, Liu Y, Li P, et al. Design and baseline characteristics of the ILD-PRO registry in patients with progressive pulmonary fibrosis. BMC Pulm Med. 2024;24(1):468. DOI:10.1186/s12890-024-03247-8
16. Julia-Serda G, Navarro-Esteva J, Doreste-Salgado L, et al. Survival and lung function changes in hypersensitivity pneumonitis according to radiological phenotypes compared with idiopathic pulmonary fibrosis. Cureus. 2024;16(3):e57307. DOI:10.7759/cureus.57307
17. Prior TS, Hilberg O, Shaker SB, et al. Validation of the King's Brief Interstitial Lung Disease questionnaire in idiopathic pulmonary fibrosis. BMC Pulm Med. 2019;19(1):255. DOI:10.1186/s12890-019-1018-0
18. D’Souza K, Ravichandran T, Venkatnarayan K, et al. Assessment of health-related quality of life in individuals with interstitial lung diseases in a tertiary care hospital in south India. Indian J Med Res. 2024;160(2):246-53. DOI:10.25259/IJMR_218_2024
19. Trushenko NV, Suvorova OA, Schmidt AE, et al. Updates on the Prevalence, Quality of Life, and Management of Chronic Cough in Interstitial Lung Diseases. Diagnostics. 2025;15(9):1139. DOI:10.3390/diagnostics15091139
20. Lee J, White E, Freiheit E, et al. Cough-specific quality of life predicts disease progression among patients with interstitial lung disease: data from the Pulmonary Fibrosis Foundation Patient Registry. Chest. 2022;162(3):603-13. DOI:10.1016/j.chest.2022.03.025
21. Khor YH, Johannson KA, Marcoux V, et al. Epidemiology and prognostic significance of cough in fibrotic interstitial lung disease. Am J Respir Crit Care Med. 2024;210(8):1035-44.
DOI:10.1164/rccm.202311-2101OC
22. Glaspole IN, Chapman SA, Cooper WA, et al. Health-related quality of life in idiopathic pulmonary fibrosis: data from the Australian IPF Registry. Respirology. 2017;22(5):950-6. DOI:10.1111/resp.12989
23. Maqhuzu PN, Szentes BL, Kreuter M, et al. Determinants of health-related quality of life decline in interstitial lung disease. Health Qual Life Outcomes. 2020;18:334. DOI:10.1186/s12955-020-01570-2
24. Szentes BL, Kreuter M, Bahmer T, et al. Quality of life assessment in interstitial lung diseases: a comparison of the disease-specific K-BILD with the generic EQ-5D-5L. Respir Res. 2018;19(1):101. DOI:10.1186/s12931-018-0808-x
________________________________________________
2. Avdeev SN, Aisanov ZR, Vizel AA, et al. Federal clinical guidelines on diagnosis and treatment of hypersensitivity pneumonitis. Pulmonologiya. 2025;35(1):16-41 (in Russian). DOI:10.18093/0869-0189-2025-35-1-16-41
3. Raghu G, Remy-Jardin M, Richeldi L, et al. Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med. 2022;205(9):e18-47. DOI:10.1164/rccm.202202-0399ST
4. Adams TN, Batra K, Kypreos M, Glazer CS. Impact of radiographic honeycombing on transplant free survival and efficacy of immunosuppression in fibrotic hypersensitivity pneumonitis. BMC Pulm Med. 2023;23(1):224. DOI:10.1186/s12890-023-02523-3
5. Aronson KI, Rajan M, Varadarajan J, et al. Development and initial validation of a disease-specific instrument to measure health-related quality of life in hypersensitivity pneumonitis. ERJ Open Res. 2024;10(4):00155-2024. DOI:10.1183/23120541.00155-2024
6. Lubin M, Chen H, Elicker B, et al. A comparison of health-related quality of life in idiopathic pulmonary fibrosis and chronic hypersensitivity pneumonitis. Chest. 2014;145(6):1333-8. DOI:10.1378/chest.13-1984
7. Patel AS, Siegert RJ, Brignall K, et al. The development and validation of the King's Brief Interstitial Lung Disease (K-BILD) health status questionnaire. Thorax. 2012;67(9):804-10. DOI:10.1136/thoraxjnl-2012-201581
8. Cox IA, Campbell J, de Graaff B, et al. Assessment of health-related quality of life in Australian patients with idiopathic pulmonary fibrosis: a comparison of the EQ-5D-5L and the AHRQL-8D. Qual Life Res. 2023;32(2):473-93. DOI:10.1007/s11136-022-03205-z
9. Takei R, Matsuda T, Fukihara J, et al. Changes in patient-reported outcomes in patients with non-idiopathic pulmonary fibrosis fibrotic interstitial lung disease and progressive pulmonary fibrosis. Front Med (Lausanne). 2023;10:1067149. DOI:10.3389/fmed.2023.1067149
10. Birring SS, Prudon B, Carr AJ, et al. Development of a symptom specific health status measure for patients with chronic cough: Leicester Cough Questionnaire (LCQ). Thorax. 2003;58(4):339-43. DOI:10.1136/thorax.58.4.339
11. Stanojevic S, Kaminsky DA, Miller MR, et al. ERS/ATS technical standard on interpretive strategies for routine lung function tests. Eur Respir J. 2022;60(1):2101499. DOI:10.1183/13993003.01499-2021
12. Rautajoki T, Rantala HA, Sutinen E, et al. Health-related quality of life measured with K-BILD is associated with survival in patients with idiopathic pulmonary fibrosis. BMC Pulm Med. 2024;24(1):480. DOI:10.1186/s12890-024-03303-3
13. Omelyanovskiy V, Musina N, Ratushnyak S, et al. Valuation of the EQ-5D-3L in Russia. Qual Life Res. 2021;30(7):1997-2007. DOI:10.1007/s11136-021-02804-6
14. Hasan S, Verma A, Haque S, et al. A clinical study to monitor prescription patterns, clinical outcomes, and adverse drug reactions among patients of various interstitial lung diseases attending respiratory medicine outpatient department at tertiary care hospital in Northern India. Perspect Clin Res. 2024;15(3):141-6. DOI:10.4103/picr.picr_108_23
15. Lobo LJ, Liu Y, Li P, et al. Design and baseline characteristics of the ILD-PRO registry in patients with progressive pulmonary fibrosis. BMC Pulm Med. 2024;24(1):468. DOI:10.1186/s12890-024-03247-8
16. Julia-Serda G, Navarro-Esteva J, Doreste-Salgado L, et al. Survival and lung function changes in hypersensitivity pneumonitis according to radiological phenotypes compared with idiopathic pulmonary fibrosis. Cureus. 2024;16(3):e57307. DOI:10.7759/cureus.57307
17. Prior TS, Hilberg O, Shaker SB, et al. Validation of the King's Brief Interstitial Lung Disease questionnaire in idiopathic pulmonary fibrosis. BMC Pulm Med. 2019;19(1):255. DOI:10.1186/s12890-019-1018-0
18. D’Souza K, Ravichandran T, Venkatnarayan K, et al. Assessment of health-related quality of life in individuals with interstitial lung diseases in a tertiary care hospital in south India. Indian J Med Res. 2024;160(2):246-53. DOI:10.25259/IJMR_218_2024
19. Trushenko NV, Suvorova OA, Schmidt AE, et al. Updates on the Prevalence, Quality of Life, and Management of Chronic Cough in Interstitial Lung Diseases. Diagnostics. 2025;15(9):1139. DOI:10.3390/diagnostics15091139
20. Lee J, White E, Freiheit E, et al. Cough-specific quality of life predicts disease progression among patients with interstitial lung disease: data from the Pulmonary Fibrosis Foundation Patient Registry. Chest. 2022;162(3):603-13. DOI:10.1016/j.chest.2022.03.025
21. Khor YH, Johannson KA, Marcoux V, et al. Epidemiology and prognostic significance of cough in fibrotic interstitial lung disease. Am J Respir Crit Care Med. 2024;210(8):1035-44.
DOI:10.1164/rccm.202311-2101OC
22. Glaspole IN, Chapman SA, Cooper WA, et al. Health-related quality of life in idiopathic pulmonary fibrosis: data from the Australian IPF Registry. Respirology. 2017;22(5):950-6. DOI:10.1111/resp.12989
23. Maqhuzu PN, Szentes BL, Kreuter M, et al. Determinants of health-related quality of life decline in interstitial lung disease. Health Qual Life Outcomes. 2020;18:334. DOI:10.1186/s12955-020-01570-2
24. Szentes BL, Kreuter M, Bahmer T, et al. Quality of life assessment in interstitial lung diseases: a comparison of the disease-specific K-BILD with the generic EQ-5D-5L. Respir Res. 2018;19(1):101. DOI:10.1186/s12931-018-0808-x
Авторы
О.А. Суворова*1, Н.В. Трушенко1,2, Б.Б. Лавгинова1, Ю.А. Левина1, З.М. Мержоева1, С.Н. Авдеев1,2
1ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет), Москва, Россия;
2ФГБУ «Научно-исследовательский институт пульмонологии» ФМБА России, Москва, Россия
*olga.a.suvorova@mail.ru
1Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia;
2Federal Pulmonology Research Institute, Moscow, Russia
*olga.a.suvorova@mail.ru
1ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет), Москва, Россия;
2ФГБУ «Научно-исследовательский институт пульмонологии» ФМБА России, Москва, Россия
*olga.a.suvorova@mail.ru
________________________________________________
1Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia;
2Federal Pulmonology Research Institute, Moscow, Russia
*olga.a.suvorova@mail.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.